Business Wire

SES

23.4.2020 08:52:11 CEST | Business Wire | Press release

Share
SES Delivers Over 8,300 TV Channels to 367 Million Homes Worldwide

SES announced today that the number of global TV households it reaches directly or indirectly via satellite has increased by 12 million to 367 million in 2019. Findings from the company’s annual Satellite Monitor market research validates, once again, SES’s position as the world’s leading video content distributor via satellite and shows the important role that satellite continues to play in reaching the largest possible audience globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422006137/en/

Much of the increase in the 12 million TV households is attributed to the leading infrastructure of TV reception – satellite and cable – which grew by 9 million in 2019 to 153 million and 149 million homes respectively. Internet Protocol TV (IPTV) and terrestrial TV grew by a combined 3 million to 43 million and 21 million homes.

The Satellite Monitor study also showed that SES’s technical reach has increased across several continents, including Europe, Africa, Asia-Pacific (APAC), and Latin America (LATAM). Europe continues to be the strongest market for SES, with 168 million total households served by the SES fleet, up by 1 million from 2018, followed by North America at 69 million.

In LATAM, SES has captured an audience of 42 million households, a significant increase from the 34 million households reported in 2018, thanks in part to the launch of a new satellite – SES 14 – which is boosting cable and IPTV growth in the region. This year also marked the first year that SES collected results from Indonesia and the Philippines. In total, SES serves 39 million APAC households with Direct-to-Home (DTH) feeds. The research also found that SES delivers digital television to 13 million households in the Middle East and 35 million homes in Africa. Altogether, SES has observed a combined growth of almost 5 million households across APAC and Africa.

SES’s TV market research sheds light on several key trends behind the relevance of satellite broadcasting, including the transition from analog to digital TV and the rise of HD broadcast. End consumers in Ghana and Nigeria are choosing satellite TV for its better value proposition and free-to-air offerings, rather than purchasing new hardware and switching to digital terrestrial TV. The Satellite Monitor study also revealed that HD broadcast has been on the rise in Europe, with 167 million TV households, an increase of 5 million from 2018. Satellite remains the preferred choice of infrastructure when it comes to HD content broadcasting, underscoring the key value proposition of satellite broadcasting as a reliable and cost-effective video delivery to large audiences.

“Broadcasters and TV platform operators need robust and reliable data before they make the decision to enter new markets. For more than 25 years, SES has been the only satellite-based solutions provider in the world to regularly and extensively monitor the industry in specific countries and identify key trends for our customers to help them succeed in their business and expand their reach,” said Ferdinand Kayser, CEO at SES Video. “The results of our annual Satellite Monitor market research demonstrate that satellite continues to be the most optimal infrastructure to deliver high picture quality, and that despite changing consumption habits, people still strongly rely on linear TV and complement it with OTT content.”

Introduced in 1994, SES’s annual Satellite Monitor research reveals the detailed technical reach of SES and valuable insights into the video market and trends worldwide. It is seen as an important tool for SES’s customers, the leading broadcasters and content owners.

Follow us on:

Social Media
Blog
Media Library

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye